IP Library Granted Patent US 10,980,590
Granted Patent B2
US 10,980,590 · App. 15/917,480 · Granted Apr 20, 2021

Devices and methods for the treatment of tissue

Inventors: Harith Rajagopalan (Wellesley Hills, MA); Jay Caplan (Belmont, MA); J. Christopher Flaherty (Auburndale, FL); Philip S. Levin (Storrs, CT)
Assignee: Fractyl Laboratories, Inc.
A61B18/00A61B17/32002A61B18/0206A61B18/042A61B18/06A61B18/1492A61B18/1815A61B18/20A61M5/178A61N7/022A61B17/3478A61B18/24A61B2017/00557A61B2017/00818A61B2017/32007A61B2018/0022A61B2018/00196A61B2018/00208A61B2018/00291A61B2018/00494A61B2018/00577A61B2018/00601A61B2018/00642A61B2018/00648A61B2018/00702A61B2018/00821A61B2018/00875A61B2018/00982A61B2018/044A61B2018/1807A61B2090/064A61B2090/065A61B2090/3614A61B2218/002A61B2218/007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,590
App. No.
15/917,480
Granted
Apr 20, 2021
Kind
B2
Abstract

Systems, methods and devices for the treatment of tissue are disclosed. A system includes an elongate tube with a distal portion. A treatment element is positioned on the elongate tube distal portion, the treatment element constructed and arranged to treat target tissue. In one embodiment, gastrointestinal tissue is modified for the treatment of diabetes.

Claims (14)

1. A treatment system for treating diabetes in a patient, the system comprising:

a body access device having a viewing component constructed and arranged to access the patient's native duodenum and allow the duodenal mucosa to be evaluated, the viewing component comprising an imaging device mounted on the body access device, the imaging device configured to provide direct visualization of internal body spaces and tissue;

a controller constructed and arranged to select a target area of the patient's duodenal mucosa to treat;

a treating component constructed and arranged to treat a treatment area of the patient's native duodenal mucosa, such that the treatment leaves the patient's duodenum anatomically intact with respect to the patient's stomach and jejunum, the treating component comprising (a) a first treatment element positioned on a distal portion of a first elongate tube, said treatment element configured to treat mucosal tissue, wherein the treatment element comprises a balloon constructed and arranged to receive a hot fluid to circumferentially deliver energy to a wall of the patient's native duodenum for controlled depth ablation of the mucosal tissue, the controller constructed and arranged to provide the hot fluid to the balloon and to adjust the pressure within the balloon and (b) a second treatment element configured to treat mucosal tissue by abrasion or ablation positioned on a second elongate tube; and

a tissue expansion device including a plurality of fluid injection needles configured to expand a full circumferential portion of submucosal tissue to increase a target treatment volume.

2. The system of claim 1 , wherein the treating component is adapted to remove the patient's duodenal mucosa and the treatment comprises eliminating stem cells in the duodenal mucosa.

3. The system of claim 1 , wherein the balloon comprises an ablative subcomponent for ablating the duodenal mucosa.

4. The system of claim 1 , wherein the treating component further comprises a shaver and/or scraper for shaving at least a portion of the duodenal mucosa.

5. The system of claim 1 , wherein the treatment element is constructed and arranged to treat one or more of: Diabetes; Type-1 Diabetes; Type-2 Diabetes; hypercholesterolemia; a metabolic syndrome; disease; celiac disease; obesity; cancer such as bronchoalveolar carcinoma; and cystitis.

6. The system of claim 1 , wherein the first elongate tube has a lumen configured to deliver the hot fluid to the balloon.

7. The system of claim 1 , wherein the treatment element is constructed and arranged to radially expand and/or radially extend to a diameter of at least 1 cm.

8. The system of claim 1 , wherein the controller is constructed and arranged to deliver the hot fluid to the balloon at a temperature of approximately 65° C. to 90° C.

9. The system of claim 1 , wherein the treatment element is constructed and arranged for closed loop energy delivery.

10. The system of claim 1 , further comprising a sensor, wherein the system is constructed and arranged to deliver energy based on signals recorded by the sensor.

Assignments (3)
SECURITY INTEREST Recorded Sep 7, 2023
From: FRACTYL HEALTH, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 064840/0561 →
CHANGE OF NAME Recorded Oct 1, 2021
From: FRACTYL LABORATORIES INC.
To: FRACTYL HEALTH, INC.
Reel/Frame 057688/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2019
From: RAJAGOPALAN, HARITH; CAPLAN, JAY; FLAHERTY, J. CHRISTOPHER; LEVIN, PHILIP S.
To: FRACTYL LABORATORIES, INC.
Reel/Frame 050931/0868 →
Continuity (5)
Continuation 13945138 · Jul 18, 2013
Continuation PCTUS2012021739 · Jan 18, 2012
Provisional Application 61434319 · Jan 19, 2011
Provisional Application 61538601 · Sep 23, 2011
Related Publication 20180193078A1 · Jul 12, 2018
Cited By (6)
US 12,201,342 US 12,303,185 US 12,364,554 US 12,396,777 US 12,478,426 US 12,690,909